Get the Stockscreener App
314.18
0.35%
1.10
After Hours:
291.00
-23.18
-7.38%
Insulet Corporation stock is traded at $314.18, with a volume of 675.13K.
It is up +0.35% in the last 24 hours and down -3.34% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
See More
Previous Close:
$313.08
Open:
$312.83
24h Volume:
675.13K
Relative Volume:
0.80
Market Cap:
$21.02B
Revenue:
$2.20B
Net Income/Loss:
$402.20M
P/E Ratio:
56.51
EPS:
5.56
Net Cash Flow:
$280.80M
1W Performance:
+2.12%
1M Performance:
-3.34%
6M Performance:
+20.34%
1Y Performance:
+55.69%
1-Day Range:
$311.78
$316.00
1-Week Range:
$304.13
$316.00
52-Week Range:
$173.00
$329.33
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
314.18 | 21.02B | 2.20B | 402.20M | 280.80M | 5.56 |
|
ABT
Abbott Laboratories
|
136.01 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
107.41 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.63 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.21 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Truist bullish on diabetes companies citing potential market growth - MSN
Insulet’s SWOT analysis: patch pump leader’s stock poised for growth By Investing.com - Investing.com South Africa
Insulet’s SWOT analysis: patch pump leader’s stock poised for growth - Investing.com
Analyst Predicts Strong Growth for Insulet (PODD) with Buy Ratin - GuruFocus
Insider Sell: Dan Manea Sells 1,300 Shares of Insulet Corp (PODD) - GuruFocus
Insulet, EyePoint & NanoDx receive $2M in tax incentives to create life sciences jobs - Worcester Business Journal
Insulet (PODD) Rated 'Buy' by Truist Securities; Price Target Set at $365 | PODD Stock News - GuruFocus
(PODD) Investment Report - news.stocktradersdaily.com
Truist initiates Insulet stock with buy rating on diabetes pump potential - Investing.com Nigeria
Truist Initiates Insulet at Buy With $365 Price Target - MarketScreener
Truist Securities Starts Insulet Corporation (PODD) at Buy - StreetInsider
Insulet’s SWOT analysis: pump maker’s stock rides wave of growth By Investing.com - Investing.com South Africa
Insulet’s SWOT analysis: pump maker’s stock rides wave of growth - Investing.com
Here's Why You Should Retain PODD Stock in Your Portfolio Now - MSN
Insulet Boosts Its Diabetes Device Via Comical Campaign -- And A Comic Book 06/12/2025 - MediaPost
Marvel’s latest superhero: Insulet’s comic book star with type 1 diabetes - Medical Marketing and Media
Insulet, Marvel collab to unveil comic book hero with type 1 diabetes - MassDevice
Possible Bearish Signals With Insulet Insiders Disposing Stock - simplywall.st
Insulet Director Cashes In on Stock Sale! - TipRanks
Insider Sell: Luciana Borio Sells Shares of Insulet Corp (PODD) - GuruFocus
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7 - MassDevice
Insulet at Goldman Sachs Conference: Strategic Growth and Leadership Transition - Investing.com Nigeria
Insulet Corporation's Omnipod 5 App for Iphone with Dexcom G7 Integration Now Available to All U.S. Users - MarketScreener
Transcript : Insulet Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 09 - MarketScreener
Insulet's Omnipod® 5 App For iPhone With Dexcom G7 Integration Now Available To All US Users - marketscreener.com
Insulet (PODD) Omnipod 5 App Now Compatible with Dexcom G7 on iPhone | PODD Stock News - GuruFocus
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration N - GuruFocus
Insulet announces Omnipod 5 App for iPhone is compatible with Dexcom G7 CGM - TipRanks
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users | PODD Stock News - GuruFocus
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users - Business Wire
Insulet To Present At Goldman Sachs Global Healthcare Conference; Webcast At 9:20 AM ET - Nasdaq
PODD Q1 Earnings Call: Insulet Highlights New Leadership and Strong Omnipod Adoption - Yahoo Finance
Insulet Corporation (PODD) Announces Credit Agreement Refinancin - GuruFocus
Insulet Corporation (PODD) Announces Credit Agreement Refinancing and Convertible Notes Redemption - GuruFocus
Insulet Issues Redemption Notice for Convertible Notes - TipRanks
Insulet enters eighth amendment to credit agreementSEC filing - MarketScreener
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
3 Medical Technology Stocks Outperforming in 2025 - MarketBeat
Raindrop Injects Personality Into Omnipod 5’s Diabetes Campaign - Little Black Book | LBBOnline
Omnipod 5 Helps Make Diabetes a Smaller Part of Life In New Work From Raindrop - citybiz
TD Cowen Raises Insulet (PODD) Price Target, Maintains Buy Rating - Insider Monkey
TD Cowen raises Insulet stock price target to $379 after strong Q1 - Investing.com Nigeria
Q1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top Marks - Yahoo Finance
Goldman Sachs Initiates Coverage of Insulet (PODD) with Buy Rating - MSN
TD Cowen raises Insulet stock price target to $379 after strong Q1 By Investing.com - Investing.com South Africa
Here's Why Insulet (PODD) is a Strong Growth Stock - Yahoo Finance
Insulet Corporation (PODD) PT Raised to $379 at TD Cowen After a Stellar 1Q - StreetInsider
TD Cowen Boosts Insulet (PODD) Price Target Following Strong Quarter | PODD Stock News - GuruFocus
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insulet Corporation Stock (PODD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Singh Prem | SVP, Global Operations |
Jun 13 '25 |
Sale |
300.05 |
2,327 |
698,216 |
4,143 |
| Manea Dan | SVP, Chief HR Officer |
Jun 13 '25 |
Sale |
300.05 |
1,300 |
390,065 |
9,090 |
0.66%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):